Maple Published April 21, 2026 · Maple Research Labs · Peptide Research
PT-141 (Bremelanotide): Melanocortin Receptor Research and Mechanism of Action
PT-141, also known as bremelanotide, is a synthetic cyclic heptapeptide analog of alpha-melanocyte-stimulating hormone (α-MSH). Originally derived from the superpotent melanocortin agonist Melanotan II, PT-141 has become one of the most studied melanocortin receptor ligands in peptide research. This article examines its molecular structure, receptor binding profile, and the body of preclinical and clinical research surrounding its mechanism of action.
Quick Reference
Sequence: Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH
CAS Number: 189691-06-3
Molecular Formula: C₅₀H₆₈N₁₄O₁₀
Molecular Weight: 1025.18 g/mol
Primary Targets: MC3R, MC4R (melanocortin receptors 3 and 4)
Route of Administration in Research: Subcutaneous, intranasal (research settings)
Origins and Development History
The melanocortin peptide system has been a subject of pharmacological interest since the isolation of α-MSH in the 1950s. Research into synthetic analogs accelerated in the 1980s and 1990s at the University of Arizona, where scientists led by Victor Hruby developed a series of superpotent melanocortin analogs.
Melanotan II (MT-II), a cyclic lactam analog of α-MSH, was synthesized as a tanning agent candidate. During Phase I clinical evaluation in the late 1990s, researchers observed unexpected physiological responses beyond melanogenesis. This observation prompted the development of PT-141, a metabolite of MT-II that retained specific receptor activity while showing a narrower binding profile (Hadley, 2005).
The structural modification from MT-II to PT-141 involved removal of the N-terminal amino acid, producing a compound with preferential activity at MC3R and MC4R over MC1R and MC5R. This selectivity shift is what makes PT-141 particularly interesting for melanocortin system research (Wikberg & Mutulis, 2008).
Melanocortin Receptor System Overview
The melanocortin system consists of five G-protein coupled receptor subtypes (MC1R through MC5R), their endogenous ligands (α-MSH, β-MSH, γ-MSH, and ACTH), and the endogenous antagonists agouti-related protein (AgRP) and agouti signaling protein (ASIP).
Each receptor subtype has a distinct tissue distribution and functional role in mammalian physiology:
MC1R — Primarily expressed in melanocytes. Regulates melanin synthesis and pigmentation. Primary target of α-MSH in the skin.
MC2R — Exclusively activated by ACTH. Found in adrenal cortex. Mediates glucocorticoid synthesis.
MC3R — Expressed in hypothalamus, limbic system, and peripheral tissues. Involved in energy homeostasis and autonomic regulation.
MC4R — Widely expressed in the CNS, particularly in hypothalamic nuclei, cortex, brainstem, and spinal cord. Central role in energy balance, autonomic function, and neuroendocrine regulation.
MC5R — Found in exocrine glands, skeletal muscle, and lymphocytes. Least characterized of the five subtypes.
PT-141 functions as a nonselective agonist with highest affinity for MC4R (Ki ≈ 2.9 nM) and MC3R (Ki ≈ 12 nM), with substantially lower affinity for MC1R and MC5R (Cai et al., 2004). It has negligible activity at MC2R.
Mechanism of Action: Central Melanocortin Signaling
PT-141’s mechanism of action operates primarily through the central nervous system, distinguishing it from peripherally-acting compounds. Upon binding to MC4R in hypothalamic nuclei, PT-141 activates Gαs-coupled signaling cascades that increase intracellular cyclic AMP (cAMP) concentrations.
The downstream signaling cascade involves several key pathways:
1. cAMP/PKA Pathway: MC4R activation stimulates adenylyl cyclase via Gαs, increasing cAMP levels. Protein kinase A (PKA) activation follows, phosphorylating CREB and other transcription factors that modulate neuropeptide expression in hypothalamic neurons (Gantz & Fong, 2003).
2. Oxytocin Neuron Activation: Research in rodent models has demonstrated that MC4R agonism in the paraventricular nucleus (PVN) of the hypothalamus activates oxytocinergic neurons projecting to the spinal cord and brainstem. This pathway appears to be a critical mediator of PT-141’s central effects (Argiolas et al., 2000).
3. Dopaminergic Modulation: MC4R activation in the medial preoptic area has been shown to increase local dopamine release in preclinical models. The interaction between melanocortin and dopaminergic systems represents an area of active investigation (Pfaus et al., 2004).
4. Nitric Oxide Signaling: Downstream of oxytocin release, nitric oxide synthase (NOS) activation has been observed in spinal cord and peripheral tissues. This NO-mediated pathway may contribute to PT-141’s effects on vascular smooth muscle in research models (Succu et al., 2007).
Preclinical Research Findings
Rodent Models
In male rat models, intracerebroventricular (ICV) administration of PT-141 at doses of 0.5-2 μg produced dose-dependent increases in penile erection frequency over a 2-hour observation period. This effect was blocked by the MC4R antagonist HS024, confirming receptor-mediated action (Martin & MacIntyre, 2004).
Female rat studies using the lordosis quotient (LQ) paradigm showed that PT-141 administration (ICV, 1 μg) significantly increased solicitation behaviors in ovariectomized, hormone-primed subjects. Notably, these effects were attenuated by oxytocin antagonist pretreatment, supporting the oxytocinergic pathway hypothesis (Pfaus et al., 2004).
Receptor Selectivity Studies
Competitive binding assays using cloned human melanocortin receptors established PT-141’s selectivity profile. Cai et al. (2004) reported the following IC50 values: MC1R = 9.2 nM, MC3R = 12.1 nM, MC4R = 2.9 nM, MC5R = 4,760 nM. The roughly 1,600-fold selectivity for MC4R over MC5R is pharmacologically significant and underpins the compound’s research utility as an MC4R probe.
Further structure-activity relationship (SAR) studies have explored modifications to the PT-141 scaffold. The D-Phe residue at position 7 has been identified as critical for MC4R agonist activity, with substitution to L-Phe resulting in >100-fold loss of potency (Hruby et al., 2007).
Clinical Research Summary
Several Phase II and Phase III clinical trials have evaluated bremelanotide (PT-141) in human subjects. Key findings from published research include:
Diamond et al. (2006): A randomized, double-blind, placebo-controlled crossover study evaluated intranasal PT-141 in male subjects with erectile dysfunction. Rigid erection response was assessed via RigiScan monitoring. Statistically significant increases in penile rigidity were observed at the 7 mg and 20 mg intranasal doses compared to placebo (p < 0.05).
Kingsberg et al. (2019): The RECONNECT Phase III program (two replicate studies, n = 1,247 combined) evaluated subcutaneous bremelanotide 1.75 mg in premenopausal women with HSDD. Both studies met their co-primary endpoints: statistically significant increases in satisfying sexual events (SSEs) and decreases in distress scores (FSDS-DAO) compared to placebo over 24 weeks.
Clayton et al. (2016): A Phase IIb dose-finding study identified 1.75 mg SC as the optimal dose in the female HSDD population, with a safety profile that included nausea (40%), flushing (20%), and headache (13%) as the most common adverse events.
Safety Considerations in Research
Published clinical data has identified several dose-dependent adverse effects that researchers should be aware of when designing studies:
Blood Pressure Effects: Early intranasal formulations at higher doses (>10 mg) were associated with transient increases in systolic blood pressure. This led to reformulation as a subcutaneous injection at 1.75 mg, which showed minimal hemodynamic effects in Phase III data (Kingsberg et al., 2019).
Nausea: The most commonly reported adverse effect across clinical trials, occurring in approximately 40% of subjects at therapeutic doses. The mechanism is believed to involve MC4R activation in the area postrema, a circumventricular organ with a reduced blood-brain barrier (Clayton et al., 2016).
Hyperpigmentation: Given PT-141’s residual MC1R activity, focal skin darkening has been observed in some subjects with repeated dosing. This is consistent with the melanogenic activity of the melanocortin system and represents a known class effect (Hadley, 2005).
Current Research Directions
Active areas of investigation involving PT-141 and the melanocortin system include:
Metabolic Research: MC4R’s established role in energy homeostasis has led to exploration of melanocortin agonists in obesity research models. PT-141’s anorectic effects in rodent models, while not its primary research application, have contributed to understanding of hypothalamic appetite circuits (Fan et al., 1997).
Neuropsychiatric Applications: The interaction between melanocortin signaling and mood-related neurotransmitter systems (dopamine, oxytocin, serotonin) has prompted investigation of MC4R modulation in animal models of depression and anxiety. Preclinical data remains preliminary (Chaki & Okuyama, 2005).
Receptor Subtype-Selective Analogs: PT-141 serves as a scaffold for developing more selective MC3R and MC4R agonists and antagonists. These tool compounds are essential for dissecting the distinct physiological roles of each receptor subtype (Hruby et al., 2007).
Handling and Storage for Research Use
Lyophilized Form: Store at -20°C. Stable for 24+ months when kept desiccated and protected from light.
Reconstituted Solution: Use bacteriostatic water or sterile saline. Store at 2-8°C and use within 28 days. Avoid repeated freeze-thaw cycles.
Light Sensitivity: PT-141 is moderately photosensitive. Store in amber vials or wrap in foil during use.
References
Argiolas, A., et al. (2000). Neuropeptides and central control of penile erection. Peptides, 21(7), 1043-1048.
Cai, M., et al. (2004). Design of novel melanotropin agonists and antagonists. Biopolymers (Peptide Science), 76(2), 98-109.
Chaki, S., & Okuyama, S. (2005). Involvement of melanocortin-4 receptor in anxiety and depression. Peptides, 26(10), 1952-1964.
Clayton, A.H., et al. (2016). Bremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled dose-finding trial. Women’s Health, 12(3), 325-337.
Diamond, L.E., et al. (2006). An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141). Journal of Sexual Medicine, 3(4), 628-638.
Fan, W., et al. (1997). Role of melanocortinergic neurons in feeding and the agouti obesity syndrome. Nature, 385(6612), 165-168.
Gantz, I., & Fong, T.M. (2003). The melanocortin system. American Journal of Physiology-Endocrinology and Metabolism, 284(3), E468-E474.
Hadley, M.E. (2005). Discovery that a melanocortin regulates sexual functions in male and female humans. Peptides, 26(10), 1687-1689.
Hruby, V.J., et al. (2007). Melanocortin receptors: from targets to drugs. Current Pharmaceutical Design, 13(6), 543-580.
Kingsberg, S.A., et al. (2019). Bremelanotide for the treatment of hypoactive sexual desire disorder: two randomized phase 3 trials. Obstetrics & Gynecology, 134(5), 899-908.
Martin, W.J., & MacIntyre, D.E. (2004). Melanocortin receptors and erectile function. European Urology, 45(6), 706-713.
Pfaus, J.G., et al. (2004). Bremelanotide induces lordosis behavior in female rats. Pharmacology Biochemistry and Behavior, 79(3), 441-448.
Succu, S., et al. (2007). Pro-VGF-derived peptides induce penile erection in male rats: possible involvement of oxytocin. European Journal of Neuroscience, 26(12), 3516-3525.
Wikberg, J.E., & Mutulis, F. (2008). Targeting melanocortin receptors: an approach to treat weight disorders and sexual dysfunction. Nature Reviews Drug Discovery, 7(4), 307-323.
Research Use Disclaimer
This article is provided for educational and research purposes only. PT-141 (bremelanotide) as supplied by Maple Research Labs is intended solely for in-vitro research and laboratory use. It is not intended for human consumption, diagnostic, or therapeutic use. Researchers are responsible for compliance with all applicable institutional and governmental regulations. Always consult your institutional review board before initiating any research protocols.
Browse our full catalog of research peptides | Read more peptide research articles
Related Research Products
Explore the research-grade peptides discussed in this article, each available with batch-specific Certificates of Analysis and same-day shipping across Canada:
Browse All Research Peptides | Research Peptide Comparison Guide